New Carotid PCI All-in-One System

Carotid stenting is equivalent to carotid endarterectomy in terms of major adverse events (death, AMI, and stroke). However, it entails higher risk of minor stroke due to micro-particle embolization, when conventional thromboembolic protection devices won’t capture them. 

Neuroguard IEP System integrates a 40-micron distal thromboembolic filter, a post-dilation balloon, and a stent, reducing catheter exchange and improving thromboembolic protection. 

The PERFORMANCE II was a prospective, multicenter, single arm study including 305 patients with significant carotid stenosis and high risk of carotid endarterectomy. 

Primary end point was a composite of death, any stroke or myocardial infarction within 30 days. 

Patients mean age was 69.6 ± 7.5 years, 65.9% were men, and 20% were symptomatic. Hypertension prevalence was 93%, and diabetes 43%. Main risk factors included hypertension, stroke or TIA in 21% of cases, and a history of endarterectomy in 10%.

25% of patients presented high risk anatomy for this procedure and nearly half had significant comorbidities. The right carotid was the most treated artery (51%), with post endarterectomy 7% restenosis rate and severe calcification in 34% of cases. 

Read also: Is Angioplasty Always Necessary after TAVR?

Primary end point was seen in 2.3% of cases, with 0.3% mortality, 1.3% stroke and 0.7% MI. At 12 months there were no neurological deaths, stroke or major stent thrombosis. Target lesion revascularization (TLR) rate was 1.1%, and incidence of any stroke 1.8%.

A subgroup analysis revealed that asymptomatic patients had a stroke/death rate of 1.2% at 30 days, vs symptomatic patients (p=0.175). stroke rate at 30 days was similar between patients under 70 or more (1.8%; p=0.633), with no significant differences in sex. (p=1.000).

Conclusion

Major adverse events rate resulted extremely low, showing its safety, efficacy and durability in high risk patients. 

Original Title: A Prospective Multicenter Investigation of a Novel Carotid Stent System: The PERFORMANCE II Trial.

Reference: William A. Gray et al. JACC: Cardiovascular Interventions, Volumen 18, 367–376, 2025.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Dr. Carlos Fava
Dr. Carlos Fava
Member of the Editorial Board of solaci.org

More articles by this author

Transcatheter Pulmonary Valve Implantation with a Self-Expanding Valve: Outcomes at 3 Years

Pulmonary regurgitation (PR) is a common condition in patients who have undergone surgical repair of Tetralogy of Fallot or other pathologies involving the right...

RACE Trial: Effect of Balloon Pulmonary Angioplasty and Riociguat on Right Ventricular Afterload and Function in Chronic Thromboembolic Pulmonary Hypertension

Even though pulmonary endarterectomy is the treatment of choice for chronic thromboembolic pulmonary hypertension (CTEPH), up to 40% of patients are not candidates because...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Cardiogenic shock (CS) remains a condition with extremely high mortality (around 50%). While most therapies for this pathology have been studied in CS secondary...